A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 5, 2008, Pages 481-487

  Gonzalez, Belen Ojeda ^a   Martin, Antonio Gonzalez ^b   Barcelo, Isabel Bover ^c   Mayol, Xavier Fabregat ^d   Mellado, Begoña ^e   Perez, María Jesus Rubio ^f   Carrion, Lorenzo Alonso ^g   Herraez, Antonio Casado ^g   Garcia, Elisa Calvo ^h   Galaz, Cristina Churruca ⁱ   Lanza, Angels Arcusa ^j   Ibañez, Ana Herrero ^k   Cebrian, Encarna Adrover ^l   Velasco, Andres Poveda ^m  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c Hospital Son Llazer   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ HOSPITAL DONOSTIA   (Spain)

^j Brain   (Spain)

^k HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^m INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

more..

Author keywords

Fixed dose rate; Gemcitabine; Ovarian cancer; Platinum resistant

Indexed keywords

CA 125 ANTIGEN; GEMCITABINE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; INFECTION; KAPLAN MEIER METHOD; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 2 CLINICAL TRIAL; SEPTIC SHOCK; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RIBONUCLEOTIDE REDUCTASES; SURVIVAL RATE;

EID: 55249089980     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31816d1c7b     Document Type: Article

References (40)

1. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG [abstract]. Proc Am Soc Clin Oncol. 2004;22:14S. Abstract 5005.
2. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′, 2′-difluorodeoxicytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994;86:1530-1533.
3. Friedlander M, Millward MJ, Bell D, et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann Oncol. 1998;9:1343-1345.
4. von Minckwitz G, Bauknecht T, Visseren-Grul CM, et al. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999;10:853-855.
5. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol. 2003;90:593-596.
6. Grunewald R, Abbruzzese JL, Tarassoff P, et al. Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991;27:258-262.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
8. Rustin GJ, Nelstrop AE, Bentzen SM, et al. Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol. 1999;10(suppl 1):S21-S27.
9. Bridgewater JA, Nelstrop AE, Rustin GJ, et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol. 1999;17:501-508.
10. Rustin GJ, Nelstrop AE, Bentzen SM, et al. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol. 2000;18:1733-1739.
11. Cancer Therapy Evaluation Program. Available at: http://ctep.cancer.gov/ forms/CTCAEv3.pdf#search=%22nci%20ctc%20version%203.0%22
12. Simon R. Optimal two-stage design for phase II clinical trials. Control Clin Trials. 1989;10:11.
13. Penson RT, Campos SM, Seiden MV, et al. A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005;15:1035-1041.
14. Veerman G, Ruiz van Haperen VW, Vermorken JB, et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′- difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol. 1996;38:335-342.
15. Brand R, Capadano M, Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs. 1997;15:331-341.
16. Garland LL, Wagner H, Shaw GS. Phase I study of constant dose rate infusion gemcitabine with taxotere in advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol. 1999;18:504a. Abstract 1946.
17. Castellano D, Hitt R, Ciruelos E, et al. Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. Ann Oncol. 2003;14:783-787.
18. Rizzieri DA, Bass AJ, Rosner GL, et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol. 2002;20:674-679.
19. Bass AJ, Gockerman JP, Hammett E, et al. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol. 2002;20:2995-3000.
20. Rizzieri DA, Ibom VK, Moore JO, et al. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clin Cancer Res. 2003;9:663-668.
21. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402-3408.
22. Guan Z, Wang Y, Maoleekoonpairoj S, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer. 2003;89:1865-1869.
23. Cappuzzo F, Novello S, De Marinis F, et al. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. Lung Cancer. 2006;52:319-325.
24. Ceribelli A, Gridelli C, De Marinis F, et al. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer. 2003;98:337-343.
25. Pereira JR, Fein L, Carvajal P, et al. Randomized phase II study of cisplatin plus gemcitabine administered either as short infusion or at a fixed dose rate in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol. 2006;24:18S. Abstract 17037.
26. Soo RA, Wang LZ, Tham LS, et al. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol. 2006;17:1128-1133.
27. Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201) [abstract]. J Clin Oncol. 2006;24:18S. Abstract 4004.
28. Ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193.
29. Gordon AN, Tonda M, Sun S, et al.; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory ovarian cancer. Gynecol Oncol. 2004;95:1-8.
30. O'Byrne KJ, Bliss P, Graham JD, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naive relapsed ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2002;21:203a. Abstract 808.
31. Rosenberg P, Andersson H, Boman K, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 2002;41:418-424.
32. Piccart M, Green J, Lacave A, et al. Oxaliplatin or paclitaxel in patients with platinum pretreated advanced ovarian cancer: a randomised phase II study of the EORTC of Cancer Gynecology Group. J Clin Oncol. 2000;18:1193-1202.
33. Vermorken J, Gore M, Perren T, et al. Multicenter randomised phase II study of oxaliplatin or topotecan in platinum-pretreated epithelial ovarian cancer patients [abstract]. Proc Am Soc Clin Oncol. 2001;20:212a. Abstract 847.
34. Mutch DG, Orlando M, Teneriello MG, et al. Randomized phase III trial of gemcitabine versus pegylated liposomal doxorubicin as second or third-line chemotherapy for platinum-resistant ovarian cancer [abstract]. Gynecol Oncol. 2006;101(suppl 1):S14. Abstract 28.
35. Bolis G, Parazzini F, Scarfone G, et al. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol. 1999;72:60-64.
36. Buda A, Floriani I, Rossi R, et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G. O.N.O. (Grappo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Br J Cancer. 2004;90:2112-2117.
37. Torri V, Floriani I, Tinazzi A, et al. Randomized trial comparing paclitaxel + doxorubicin (AT) versus paclitaxel (T) as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum based chemotherapy [abstract]. Proc Am Soc Clin Oncol. 2000;19:381a. Abstract 1506.
38. Gonzalez-Martin A; for GEICO Group. Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy. Int J Gynecol Cancer. 2005;15(suppl 3):S241-S246.
39. Sehouli J, Sommer H, Klare P, et al. A randomized multicenter phase III trial of topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine for second-line treatment of recurrent ovarian cancer [abstract]. Proc Am Soc Clin Oncol. 2006;24:18S. Abstract 5030.
40. Gonzalez-Martin AJ. Medical treatment of epithelial ovarian cancer. Expert Rev Anticancer Ther. 2004;4:1125-1143.